Proteasome inhibitor (PI) remedy has improved the survival of a number of myeloma (MM) sufferers. Nevertheless, inevitably, major or acquired resistance to PIs results in illness development; resistance mechanisms are unclear. Weight problems is a danger issue for MM mortality. Oxidized LDL (OxLDL), a central mediator of atherosclerosis that’s elevated in metabolic syndrome (co-occurrence of weight problems, insulin resistance, dyslipidemia and hypertension), has been linked to an elevated danger of strong cancers and proven to stimulate pro-oncogenic/survival signaling.
We hypothesized that OxLDL is a mediator of chemoresistance, and evaluated its results on MM cell killing by PIs. OxLDL potently suppressed the flexibility of the boronic-acid primarily based PIs bortezomib (BTZ) and ixazomib, however not the epoxyketone-based PI carfilzomib, to kill human MM cell traces and first cells. OxLDL suppressed BTZ-induced inhibition of proteasome exercise and induction of pro-apoptotic signaling. These cytoprotective results have been abrogated when lipid hydroperoxides (LOOHs) related to OxLDL have been enzymatically diminished.
We additionally demonstrated the presence of OxLDL within the MM bone marrow microenvironment in addition to quite a few granulocytes and monocytes able to cell-mediated LDL oxidation via myeloperoxidase. Our findings recommend that OxLDL could also be a potent mediator of boronic acid-based PI resistance, significantly for MM sufferers with metabolic syndrome, given their elevated systemic ranges of OxLDL. LDL cholesterol-lowering remedy to cut back circulating OxLDL, and pharmacologic concentrating on of LOOH ranges or resistance pathways induced by the modified lipoprotein, might deepen the response to those necessary brokers and supply scientific profit to MM sufferers with metabolic syndrome. This text is protected by copyright. All rights reserved.
Utilizing Genetic Engineering Methods to Develop Banana Cultivars With Fusarium Wilt Resistance and Splendid Plant Structure
Bananas (Musa spp.) are an necessary fruit crop worldwide. The fungus Fusarium oxysporum f. sp. cubense (Foc), which causes Fusarium wilt, is extensively considered some of the damaging plant illnesses. Fusarium wilt has beforehand devastated international banana manufacturing and continues to take action immediately. As well as, because of the present use of high-density banana plantations, fascinating banana varieties with splendid plant structure (IPA) possess excessive lodging resistance, optimum photosynthesis, and environment friendly water absorption. These properties might assist to extend banana manufacturing.
Genetic engineering is beneficial for the event of banana varieties with Foc resistance and splendid plant structure because of the sterility of most cultivars. Nevertheless, the sustained immune response caused by genetic engineering is all the time accompanied by yield reductions. To resolve this downside, we must always carry out purposeful genetic research of the Musa genome, at the side of genome modifying experiments, to unravel the molecular mechanisms underlying the immune response and the formation of plant structure within the banana. Additional explorations of the genes related to Foc resistance and splendid structure would possibly result in the event of banana varieties with each splendid structure and pathogen super-resistance. Such varieties will assist the banana to stay a staple meals worldwide.
Analysis of Hippo Pathway and CD133 in Radiation Resistance in Small-Cell Lung Most cancers
Though the Hippo pathway and CD133 have been reported to play pertinent roles in a wide range of most cancers, information about their contribution to radiation resistance in small-cell lung most cancers (SCLC) is restricted. On this first-of-a-kind examine, we’ve got reported the expression of key Hippo pathway proteins in SCLC sufferers by immunohistochemical staining. We assessed the involvement of yes-associated protein 1 (YAP1) in radiation resistance by Cell Counting Equipment-8 (CCK-8) and circulate cytometry.

As well as, we analysed the impression of CD133 on radiotherapy for SCLC. The mammalian Ste20-like serine/threonine kinase 2(MST2), pMST2, and pYAP1 within the Hippo pathway weren’t considerably related to the illness stage and survival time in sufferers with SCLC. Nevertheless, the pYAP1 expression confirmed some significance within the “YAP/TAZ subgroup” of SCLC sufferers. The proportion of CD133 within the SCLC cells was managed by the YAP1 expression.
The CD133 and YAP1 ranges have been considerably correlation with one another in tissues of SCLC sufferers. We sorted and remoted the CD133+ and CD133–cells in H69 and located that the cell floor glycoprotein could also be related to the radiation resistance of SCLC.In abstract, we’ve got firstly reported the expression of key Hippo pathway proteins in SCLC sufferers. Moreover, we additionally recognized that CD133 could also be managed by the expression of YAP1 within the Hippo pathway and that CD133 could also be related to the radiation resistance of SCLC.
Histology and RNA Sequencing Present Insights Into Fusarium Head Blight Resistance in AAC Tenacious
Fusarium head blight (FHB) is a critical fungal illness affecting wheat and different cereals worldwide. This fungus causes extreme yield and high quality losses from a discount in grain high quality and contamination of grain with mycotoxins. Intensive breeding efforts led to the discharge of AAC Tenacious, which was the primary spring wheat cultivar registered in Canada with a resistant (R) score to FHB. To elucidate the physiological mechanisms of resistance, we carried out histological and transcriptomic analyses of AAC Tenacious and a prone management Roblin after inoculation with Fusarium graminearum (Fg).
The spikelet and rachis of contaminated wheat spikes have been hand sectioned and monitored by confocal and fluorescent microscopy. Seen hyphae have been noticed throughout the inoculated spikelets for AAC Tenacious; nevertheless, the an infection was largely restricted to the purpose of inoculation (POI), whereas the adjoining florets in Roblin have been closely contaminated. Important cell wall thickening throughout the rachis node beneath the POI was evident in AAC Tenacious in comparison with Roblin in response to Fg inoculation.
Erythromycin resistance peptide |
5-01118 |
CHI Scientific |
4 x 5mg |
Ask for price |
Caspase 5 Inhibitor Drug Screening Kit |
55R-1332 |
Fitzgerald |
100 assays |
EUR 743 |
Description: Screening Kit for detection of Caspase 5 Inhibitor activity in the research laboratory |
Thymidylate Synthase (5-FU Resistance Marker); Clone TS106 (Concentrate) |
RA0326-C.5 |
ScyTek Laboratories |
0.5 ml |
EUR 300 |
Thymidylate Synthase (5-FU Resistance Marker); Clone TMS715 (Concentrate) |
RA0327-C.5 |
ScyTek Laboratories |
0.5 ml |
EUR 300 |
Thymidylate Synthase (5-FU Resistance Marker); Clone TS106 & TMS715 (Concentrate) |
RA0328-C.5 |
ScyTek Laboratories |
0.5 ml |
EUR 300 |
Ketolide resistance Peptide MRFFV |
5-01423 |
CHI Scientific |
4 x 5mg |
Ask for price |
Caspase-5 Inhibitor Drug Screening Kit (Fluorometric) |
K2161-100 |
ApexBio |
100 assays |
EUR 599 |
Caspase-5 Inhibitor Drug Screening Kit (Fluorometric) |
K155-100 |
Biovision |
|
EUR 555 |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361) Antibody |
BNUM1361-50 |
Biotium |
50uL |
EUR 395 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361), 1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362) Antibody |
BNUM1362-50 |
Biotium |
50uL |
EUR 395 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362), 1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361) Antibody |
BNUB1361-100 |
Biotium |
100uL |
EUR 209 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361), Concentration: 0.2mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361) Antibody |
BNUB1361-500 |
Biotium |
500uL |
EUR 458 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361), Concentration: 0.2mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362) Antibody |
BNUB1362-100 |
Biotium |
100uL |
EUR 209 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362), Concentration: 0.2mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362) Antibody |
BNUB1362-500 |
Biotium |
500uL |
EUR 458 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362), Concentration: 0.2mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361) Antibody |
BNC551361-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361),CF555 conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361) Antibody |
BNC551361-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361),CF555 conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362) Antibody |
BNC551362-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362),CF555 conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362) Antibody |
BNC551362-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362),CF555 conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361) Antibody |
BNC611361-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361),CF660R conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361) Antibody |
BNC611361-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361),CF660R conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362) Antibody |
BNC611362-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362),CF660R conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362) Antibody |
BNC611362-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362),CF660R conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361) Antibody |
BNC471361-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361),CF647 conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361) Antibody |
BNC471361-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361),CF647 conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362) Antibody |
BNC471362-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362),CF647 conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362) Antibody |
BNC471362-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362),CF647 conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361) Antibody |
BNC051361-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361),CF405M conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361) Antibody |
BNC051361-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361),CF405M conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362) Antibody |
BNC051362-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362),CF405M conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362) Antibody |
BNC051362-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362),CF405M conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361) Antibody |
BNC401361-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361),CF640R conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361) Antibody |
BNC401361-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361),CF640R conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362) Antibody |
BNC401362-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362),CF640R conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362) Antibody |
BNC401362-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362),CF640R conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361) Antibody |
BNC431361-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361),CF543 conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361) Antibody |
BNC431361-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361),CF543 conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362) Antibody |
BNC431362-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362),CF543 conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362) Antibody |
BNC431362-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362),CF543 conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361) Antibody |
BNC041361-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361),CF405S conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361) Antibody |
BNC041361-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361),CF405S conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362) Antibody |
BNC041362-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362),CF405S conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362) Antibody |
BNC041362-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362),CF405S conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361) Antibody |
BNC701361-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361),CF770 conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361) Antibody |
BNC701361-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361),CF770 conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362) Antibody |
BNC701362-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362),CF770 conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362) Antibody |
BNC701362-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362),CF770 conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361) Antibody |
BNC801361-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361),CF680 conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361) Antibody |
BNC801361-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361),CF680 conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362) Antibody |
BNC801362-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362),CF680 conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362) Antibody |
BNC801362-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362),CF680 conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361) Antibody |
BNCP1361-250 |
Biotium |
250uL |
EUR 383 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361),PerCP conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362) Antibody |
BNCP1362-250 |
Biotium |
250uL |
EUR 383 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362),PerCP conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361) Antibody |
BNCR1361-250 |
Biotium |
250uL |
EUR 383 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361),RPE conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362) Antibody |
BNCR1362-250 |
Biotium |
250uL |
EUR 383 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362),RPE conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361) Antibody |
BNCA1361-250 |
Biotium |
250uL |
EUR 383 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361),APC conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362) Antibody |
BNCA1362-250 |
Biotium |
250uL |
EUR 383 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362),APC conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361) Antibody |
BNCB1361-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361),Biotin conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361) Antibody |
BNCB1361-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361),Biotin conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362) Antibody |
BNCB1362-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362),Biotin conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362) Antibody |
BNCB1362-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362),Biotin conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361) Antibody |
BNCH1361-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361),Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361) Antibody |
BNCH1361-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361),Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362) Antibody |
BNCH1362-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362),Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362) Antibody |
BNCH1362-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362),Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361) Antibody |
BNC881361-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361),CF488A conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361) Antibody |
BNC881361-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361),CF488A conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362) Antibody |
BNC881362-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362),CF488A conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362) Antibody |
BNC881362-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362),CF488A conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361) Antibody |
BNC941361-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361),CF594 conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361) Antibody |
BNC941361-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361),CF594 conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362) Antibody |
BNC941362-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362),CF594 conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362) Antibody |
BNC941362-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362),CF594 conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361) Antibody |
BNC681361-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361),CF568 conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361) Antibody |
BNC681361-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361),CF568 conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362) Antibody |
BNC681362-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362),CF568 conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362) Antibody |
BNC681362-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362),CF568 conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361) Antibody |
BNCAP1361-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361),Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361) Antibody |
BNCAP1361-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361),Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362) Antibody |
BNCAP1362-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362),Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362) Antibody |
BNCAP1362-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362),Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361) Antibody |
BNC811361-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361),CF680R conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361) Antibody |
BNC811361-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1361),CF680R conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362) Antibody |
BNC811362-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362),CF680R conjugate, Concentration: 0.1mg/mL |
Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362) Antibody |
BNC811362-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) (TOP2A/1362),CF680R conjugate, Concentration: 0.1mg/mL |
Anti-Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) Monoclonal Antibody |
M00953 |
BosterBio |
100ug/vial |
EUR 397 |
Description: Mouse Monoclonal Topoisomerase II alpha (Proliferation & Drug-Resistance Marker) Antibody. Validated in IHC and tested in Human, Mouse. |
Multidrug Resistance-Associated Protein 5 (MRP5) Antibody |
abx235311-100ug |
Abbexa |
100 ug |
EUR 481 |
- Shipped within 5-12 working days.
|
Multidrug Resistance-Associated Protein 5 (MRP5) Antibody |
abx431874-200ul |
Abbexa |
200 ul |
EUR 384 |
- Shipped within 1-3 working days.
|
Human Lung resistance-related protein,LRP ELISA Kit |
201-12-1076 |
SunredBio |
96 tests |
EUR 440 |
- This Lung resistance-related protein ELISA kit is validated to work with samples from whole blood, serum, plasma and cell culture supernatant.
|
Description: A quantitative ELISA kit for measuring Human in samples from biological fluids. |
Human Lung resistance-related protein,LRP ELISA Kit |
CN-04375H1 |
ChemNorm |
96T |
EUR 458 |
Human Lung resistance-related protein,LRP ELISA Kit |
CN-04375H2 |
ChemNorm |
48T |
EUR 307 |
Human Lung resistance-related protein(LRP)ELISA Kit |
GA-E1092HM-48T |
GenAsia Biotech |
48T |
EUR 289 |
Human Lung resistance-related protein(LRP)ELISA Kit |
GA-E1092HM-96T |
GenAsia Biotech |
96T |
EUR 466 |
Autophagy Related 5 |
PR27229 |
Neuromics |
2 ug |
EUR 191 |
ELISA kit for Human LRP (Lung Resistance-Related Protein) |
E-EL-H1271 |
Elabscience Biotech |
1 plate of 96 wells |
EUR 534 |
- Gentaur's LRP ELISA kit utilizes the Sandwich-ELISA principle. The micro ELISA plate provided in this kit has been pre-coated with an antibody specific to Human LRP. Standards or samples are added to the micro ELISA plate wells and combined with the
- Show more
|
Description: A sandwich ELISA kit for quantitative measurement of Human LRP (Lung Resistance-Related Protein) in samples from Serum, Plasma, Cell supernatant |
Multi-species Nuclear Receptor Related Protein 1 (NURR1) ELISA Kit |
SED964Mi-10x96wellstestplate |
Cloud-Clone |
10x96-wells test plate |
EUR 4862.4 |
- The Intra-assay Precision is determined when 3 samples with low, middle and high level of Multi-species Nuclear Receptor Related Protein 1 (NURR1) were tested on 3 different plates, 8 replicates in each plate
- CV(%) = SD/meanX100
- Intra-Assay: CV<10%
- Show more
|
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Multi-species Nuclear Receptor Related Protein 1 (NURR1) in Tissue homogenates, cell lysates and other biological fluids. |
Multi-species Nuclear Receptor Related Protein 1 (NURR1) ELISA Kit |
SED964Mi-1x48wellstestplate |
Cloud-Clone |
1x48-wells test plate |
EUR 488.08 |
- The Intra-assay Precision is determined when 3 samples with low, middle and high level of Multi-species Nuclear Receptor Related Protein 1 (NURR1) were tested on 3 different plates, 8 replicates in each plate
- CV(%) = SD/meanX100
- Intra-Assay: CV<10%
- Show more
|
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Multi-species Nuclear Receptor Related Protein 1 (NURR1) in Tissue homogenates, cell lysates and other biological fluids. |
Multi-species Nuclear Receptor Related Protein 1 (NURR1) ELISA Kit |
SED964Mi-1x96wellstestplate |
Cloud-Clone |
1x96-wells test plate |
EUR 654.4 |
- The Intra-assay Precision is determined when 3 samples with low, middle and high level of Multi-species Nuclear Receptor Related Protein 1 (NURR1) were tested on 3 different plates, 8 replicates in each plate
- CV(%) = SD/meanX100
- Intra-Assay: CV<10%
- Show more
|
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Multi-species Nuclear Receptor Related Protein 1 (NURR1) in Tissue homogenates, cell lysates and other biological fluids. |
Multi-species Nuclear Receptor Related Protein 1 (NURR1) ELISA Kit |
SED964Mi-5x96wellstestplate |
Cloud-Clone |
5x96-wells test plate |
EUR 2644.8 |
- The Intra-assay Precision is determined when 3 samples with low, middle and high level of Multi-species Nuclear Receptor Related Protein 1 (NURR1) were tested on 3 different plates, 8 replicates in each plate
- CV(%) = SD/meanX100
- Intra-Assay: CV<10%
- Show more
|
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Multi-species Nuclear Receptor Related Protein 1 (NURR1) in Tissue homogenates, cell lysates and other biological fluids. |
Multi-species Nuclear Receptor Related Protein 1 (NURR1) ELISA Kit |
4-SED964Mi |
Cloud-Clone |
-
EUR 4913.00
-
EUR 2595.00
-
EUR 655.00
|
-
10 plates of 96 wells
-
5 plates of 96 wells
-
1 plate of 96 wells
|
- Known also as Nuclear Receptor Related Protein 1 elisa. Alternative names of the recognized antigen: NR4A2
- RNR1
- HZF-3
- NOT
- TINUR
- Nuclear Receptor Subfamily 4, Group A, Member 2
- Transcriptionally-inducible nuclear receptor
- Immediate-early respon
- Show more
|
Description: Enzyme-linked immunosorbent assay based on the Double-antibody Sandwich method for detection of Multi-species Nuclear Receptor Related Protein 1 (NURR1) in samples from Tissue homogenates, cell lysates and other biological fluids with no significant corss-reactivity with analogues from other species. |
MRP1 / ABCC1 (Multidrug Resistance Related Protein 1) (MRP1/1343) Antibody |
BNUM1343-50 |
Biotium |
50uL |
EUR 395 |
Description: Primary antibody against MRP1 / ABCC1 (Multidrug Resistance Related Protein 1) (MRP1/1343), 1mg/mL |
MRP1 / ABCC1 (Multidrug Resistance Related Protein 1) (MRP1/1344) Antibody |
BNUM1344-50 |
Biotium |
50uL |
EUR 395 |
Description: Primary antibody against MRP1 / ABCC1 (Multidrug Resistance Related Protein 1) (MRP1/1344), 1mg/mL |
MRP1 / ABCC1 (Multidrug Resistance Related Protein 1) (MRP1/1343) Antibody |
BNUB1343-100 |
Biotium |
100uL |
EUR 209 |
Description: Primary antibody against MRP1 / ABCC1 (Multidrug Resistance Related Protein 1) (MRP1/1343), Concentration: 0.2mg/mL |
MRP1 / ABCC1 (Multidrug Resistance Related Protein 1) (MRP1/1343) Antibody |
BNUB1343-500 |
Biotium |
500uL |
EUR 458 |
Description: Primary antibody against MRP1 / ABCC1 (Multidrug Resistance Related Protein 1) (MRP1/1343), Concentration: 0.2mg/mL |
MRP1 / ABCC1 (Multidrug Resistance Related Protein 1) (MRP1/1344) Antibody |
BNUB1344-100 |
Biotium |
100uL |
EUR 209 |
Description: Primary antibody against MRP1 / ABCC1 (Multidrug Resistance Related Protein 1) (MRP1/1344), Concentration: 0.2mg/mL |
MRP1 / ABCC1 (Multidrug Resistance Related Protein 1) (MRP1/1344) Antibody |
BNUB1344-500 |
Biotium |
500uL |
EUR 458 |
Description: Primary antibody against MRP1 / ABCC1 (Multidrug Resistance Related Protein 1) (MRP1/1344), Concentration: 0.2mg/mL |
MRP1 / ABCC1 (Multidrug Resistance Related Protein 1) (MRP1/1343) Antibody |
BNC551343-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against MRP1 / ABCC1 (Multidrug Resistance Related Protein 1) (MRP1/1343),CF555 conjugate, Concentration: 0.1mg/mL |
MRP1 / ABCC1 (Multidrug Resistance Related Protein 1) (MRP1/1343) Antibody |
BNC551343-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against MRP1 / ABCC1 (Multidrug Resistance Related Protein 1) (MRP1/1343),CF555 conjugate, Concentration: 0.1mg/mL |
MRP1 / ABCC1 (Multidrug Resistance Related Protein 1) (MRP1/1344) Antibody |
BNC551344-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against MRP1 / ABCC1 (Multidrug Resistance Related Protein 1) (MRP1/1344),CF555 conjugate, Concentration: 0.1mg/mL |
MRP1 / ABCC1 (Multidrug Resistance Related Protein 1) (MRP1/1344) Antibody |
BNC551344-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against MRP1 / ABCC1 (Multidrug Resistance Related Protein 1) (MRP1/1344),CF555 conjugate, Concentration: 0.1mg/mL |
MRP1 / ABCC1 (Multidrug Resistance Related Protein 1) (MRP1/1343) Antibody |
BNC611343-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against MRP1 / ABCC1 (Multidrug Resistance Related Protein 1) (MRP1/1343),CF660R conjugate, Concentration: 0.1mg/mL |
MRP1 / ABCC1 (Multidrug Resistance Related Protein 1) (MRP1/1343) Antibody |
BNC611343-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against MRP1 / ABCC1 (Multidrug Resistance Related Protein 1) (MRP1/1343),CF660R conjugate, Concentration: 0.1mg/mL |
MRP1 / ABCC1 (Multidrug Resistance Related Protein 1) (MRP1/1344) Antibody |
BNC611344-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against MRP1 / ABCC1 (Multidrug Resistance Related Protein 1) (MRP1/1344),CF660R conjugate, Concentration: 0.1mg/mL |
MRP1 / ABCC1 (Multidrug Resistance Related Protein 1) (MRP1/1344) Antibody |
BNC611344-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against MRP1 / ABCC1 (Multidrug Resistance Related Protein 1) (MRP1/1344),CF660R conjugate, Concentration: 0.1mg/mL |
MRP1 / ABCC1 (Multidrug Resistance Related Protein 1) (MRP1/1343) Antibody |
BNC471343-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against MRP1 / ABCC1 (Multidrug Resistance Related Protein 1) (MRP1/1343),CF647 conjugate, Concentration: 0.1mg/mL |
MRP1 / ABCC1 (Multidrug Resistance Related Protein 1) (MRP1/1343) Antibody |
BNC471343-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against MRP1 / ABCC1 (Multidrug Resistance Related Protein 1) (MRP1/1343),CF647 conjugate, Concentration: 0.1mg/mL |
MRP1 / ABCC1 (Multidrug Resistance Related Protein 1) (MRP1/1344) Antibody |
BNC471344-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against MRP1 / ABCC1 (Multidrug Resistance Related Protein 1) (MRP1/1344),CF647 conjugate, Concentration: 0.1mg/mL |
MRP1 / ABCC1 (Multidrug Resistance Related Protein 1) (MRP1/1344) Antibody |
BNC471344-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against MRP1 / ABCC1 (Multidrug Resistance Related Protein 1) (MRP1/1344),CF647 conjugate, Concentration: 0.1mg/mL |
MRP1 / ABCC1 (Multidrug Resistance Related Protein 1) (MRP1/1343) Antibody |
BNC051343-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against MRP1 / ABCC1 (Multidrug Resistance Related Protein 1) (MRP1/1343),CF405M conjugate, Concentration: 0.1mg/mL |
MRP1 / ABCC1 (Multidrug Resistance Related Protein 1) (MRP1/1343) Antibody |
BNC051343-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against MRP1 / ABCC1 (Multidrug Resistance Related Protein 1) (MRP1/1343),CF405M conjugate, Concentration: 0.1mg/mL |
MRP1 / ABCC1 (Multidrug Resistance Related Protein 1) (MRP1/1344) Antibody |
BNC051344-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against MRP1 / ABCC1 (Multidrug Resistance Related Protein 1) (MRP1/1344),CF405M conjugate, Concentration: 0.1mg/mL |
MRP1 / ABCC1 (Multidrug Resistance Related Protein 1) (MRP1/1344) Antibody |
BNC051344-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against MRP1 / ABCC1 (Multidrug Resistance Related Protein 1) (MRP1/1344),CF405M conjugate, Concentration: 0.1mg/mL |
Rachis node and rachilla tissues from the POI and the rachis node beneath the POI have been collected at 5 days publish inoculation for RNAseq. Important modifications in gene expression have been detected in each cultivars in response to an infection. The rachis node beneath the POI in AAC Tenacious had fewer differentially expressed genes (DEGs) when in comparison with the uninoculated management, possible on account of its elevated illness resistance. Evaluation of DEGs in Roblin and AAC Tenacious revealed the activation of genes and pathways in response to an infection, together with these putatively concerned in cell wall modification and protection response.